Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences is poised for growth with its suite of AI-ECG diagnostic solutions and cloud-based platform, MyoVista Insights. Despite the need for additional financing, the company has multiple facilities in place to address this issue. The recent FDA submission for the MyoVista wavECG device is a significant milestone and the company's careful spending has resulted in a lower cash burn rate and improved earnings estimates. Risks include dilution, execution challenges, and regulatory hurdles, but with a NPV analysis pointing to 3x upside potential and favorable risk/reward, HeartSciences presents an attractive opportunity for investors.

Bears say

HeartSciences is striving towards a promising and valuable use of AI in the medical field, with its MyoVista device and cloud software platform being approved and positioned to capture a large portion of the US annual ECG tests. With a current focus on early detection and prevention, and a potential to save lives and reduce healthcare costs, the company's revenues are expected to be significant and could result in long-term success. Additionally, operating expenses remain at a manageable level and a recent equity financing has increased the number of shares, indicating a healthy growth trajectory.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.